Hub genes and key pathways of non‑small lung cancer identified using bioinformatics

Tang,Qing; Zhang,Hongmei; Kong,Man; Mao,Xiaoli; Cao,Xiaocui

doi:10.3892/ol.2018.8882

Hub genes and key pathways of non‑small lung cancer identified using bioinformatics

Authors:
- Qing Tang
- Hongmei Zhang
- Man Kong
- Xiaoli Mao
- Xiaocui Cao
View Affiliations

Affiliations: Department of Clinical Laboratory, Tongji Hospital, Wuhan, Hubei 430014, P.R. China, Department of Clinical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: June 4, 2018 https://doi.org/10.3892/ol.2018.8882
Pages: 2344-2354
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for ~80% of all lung cancer cases. The aim of the present study was to identify key genes and pathways in NSCLC, in order to improve understanding of the mechanism of lung cancer. The GSE33532 gene expression dataset, containing 20 normal and 80 NSCLC samples, was used. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to obtain the enrichment data of differently expressed genes (DEGs). Disease modules within NSCLC were constructed by Cytoscape, using protein‑protein interaction (PPI) from the Search Tool for the Retrieval of Interacting Genes database. In addition, the Kaplan Meier plotter KMplot was used to assess the top hub genes in the PPI network. As a result, 1,795 genes were identified in NSCLC; 729 were upregulated and 1,066 were downregulated. The results of the GO analysis indicated that the upregulated DEGs were significantly enriched in ‘biological processes’ (BP), including ‘cell cycle and nuclear division’; the downregulated DEGs were also significantly enriched in BP, including ‘response to wounding’, ‘anatomical structure morphogenesis’ and ‘response to stimulus’. Upregulated DEGs were also enriched in ‘cell cycle’, ‘DNA replication’ and the ‘tumor protein 53 signaling pathway’, while the downregulated DEGs were also enriched in ‘complement and coagulation cascades’, ‘malaria’ and ‘cell adhesion molecules’. The top 9 hub genes were cyclin‑dependent kinase 9 (CDK1), polo‑like kinase 1, aurora kinase B, cell division cycle 20, baculoviral initiator of apoptosis repeat containing 5, mitotic checkpoint serine/threonine kinase B, proliferating cell nuclear antigen (PCNA), centromere protein A and MAD2 mitotic arrest deficient‑like 1, and the KMplot results revealed that the high expression levels of these genes resulted in significantly low survival rates, compared with low expression samples (P<0.05), with the exception of PCNA and CDK1. In the pathway crosstalk analysis, 26 nodes and 41 interactions were divided into two groups: One module of the two groups primarily included ‘metabolism of amino acid’ and the other primarily contained ‘tumor necrosis signaling’ pathways. In conclusion, the present study assisted in improving the understanding of the molecular mechanisms underlying NSCLC development, and the results may help the understanding of the biological mechanism of NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
3	Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, et al: Non-small cell lung cancer. J Natl Compr Canc Netw. 10:1236–1271. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bejjani BA and Shaffer LG: Clinical utility of contemporary molecular cytogenetics. Annu Rev Genomics Hum Genet. 9:71–86. 2008. View Article : Google Scholar : PubMed/NCBI
5	Zhang C, Li HR, Fan JB, Wang-Rodriguez J, Downs T, Fu XD and Zhang MQ: Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics. 7:2022006. View Article : Google Scholar : PubMed/NCBI
6	Zhu M, Deng X, Joshi T, Xu D, Stacey G and Cheng J: Reconstructing differentially co-expressed gene modules and regulatory networks of soybean cells. BMC Genomics. 13:4372012. View Article : Google Scholar : PubMed/NCBI
7	Denoix PF: Enquete permanent dans les centres anticancereaux. Bull Inst Nat Hyg. 1:70–75. 1946.(In French).
8	Meister M, Belousov A, Xu EC, et al: Intra-tumor heterogeneity of gene expression profiles in early stage non-small cell lung cancer. J Bioinf Res Stud. 1:12014.
9	Gautier L, Cope L, Bolstad BM and Irizarry RA: Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
10	Phipson B, Lee S, Majewski IJ, Alexander WS and Smyth GK: Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression. Ann Appl Stat. 10:946–963. 2016. View Article : Google Scholar : PubMed/NCBI
11	Martucci D, Masseroli M and Pinciroli F: Gene ontology application to genomic functional annotation, statistical analysis and knowledge mining. Stud Health Technol Inform. 102:108–131. 2004.PubMed/NCBI
12	Kanehisa M: The KEGG database. Novartis Found Symp. 247:91–103, 119-128, 244–152. 2002. View Article : Google Scholar : PubMed/NCBI
13	Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4:P32003. View Article : Google Scholar : PubMed/NCBI
14	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
15	Langley SR, Dwyer J, Drozdov I, Yin X and Mayr M: Proteomics: From single molecules to biological pathways. Cardiovasc Res. 97:612–622. 2013. View Article : Google Scholar : PubMed/NCBI
16	Burrell RA, McGranahan N, Bartek J and Swanton C: The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 501:338–345. 2013. View Article : Google Scholar : PubMed/NCBI
17	Liu M, Fan R, Liu X, Cheng F and Wang J: Pathways and networks-based analysis of candidate genes associated with nicotine addiction. PLoS One. 10:e01274382015. View Article : Google Scholar : PubMed/NCBI
18	Szasz AM, Lanczky A, Nagy A, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
19	Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
20	Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015. View Article : Google Scholar : PubMed/NCBI
21	An Q, Han C, Zhou Y, Li F, Li D, Zhang X, Yu Z, Duan Z and Kan Q: Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. Mol Med Rep. 14:4042–4048. 2016. View Article : Google Scholar : PubMed/NCBI
22	Jung CK, Jung JH, Lee KY, Kang CS, Kim M, Ko YH and Oh CS: Centrosome abnormalities in non-small cell lung cancer: correlations with DNA aneuploidy and expression of cell cycle regulatory proteins. Pathol Res Pract. 203:839–847. 2007. View Article : Google Scholar : PubMed/NCBI
23	Rao PC, Begum S, Jahromi MA, Jahromi ZH, Sriram S and Sahai M: Cytotoxicity of withasteroids: Withametelin induces cell cycle arrest at G2/M phase and mitochondria-mediated apoptosis in non-small cell lung cancer A549 cells. Tumour Biol. 37:12579–12587. 2016. View Article : Google Scholar : PubMed/NCBI
24	Wang L, Xu J, Zhao C, Zhao L and Feng B: Antiproliferative, cell-cycle dysregulation effects of novel asiatic acid derivatives on human non-small cell lung cancer cells. Chem Pharm Bull (Tokyo). 61:1015–1023. 2013. View Article : Google Scholar : PubMed/NCBI
25	Haura EB: Is repetitive wounding and bone marrow-derived stem cell mediated-repair an etiology of lung cancer development and dissemination? Med Hypotheses. 67:951–956. 2006. View Article : Google Scholar : PubMed/NCBI
26	Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA and Tsao MS: Inhibiting MDM2-p53 interaction suppresses tumor growth in patient-derived non-small cell lung cancer xenograft models. J Thorac Oncol. 10:1172–1180. 2015. View Article : Google Scholar : PubMed/NCBI
27	In JK, Kim JK, Oh JS and Seo DW: 5-Caffeoylquinic acid inhibits invasion of non-small cell lung cancer cells through the inactivation of p70S6K and Akt activity: Involvement of p53 in differential regulation of signaling pathways. Int J Oncol. 48:1907–1912. 2016. View Article : Google Scholar : PubMed/NCBI
28	Fukushi S, Yoshino H, Yoshizawa A and Kashiwakura I: p53-independent structure-activity relationships of 3-ring mesogenic compounds' activity as cytotoxic effects against human non-small cell lung cancer lines. BMC Cancer. 16:5212016. View Article : Google Scholar : PubMed/NCBI
29	Albelda SM and Buck CA: Integrins and other cell adhesion molecules. FASEB J. 4:2868–2880. 1990. View Article : Google Scholar : PubMed/NCBI
30	Hall CL and Turley EA: Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. J Neurooncol. 26:221–229. 1995. View Article : Google Scholar : PubMed/NCBI
31	Tong Y, Liu Y, Zheng H, Zheng L, Liu W, Wu J, Ou R, Zhang G, Li F, Hu M, et al: Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling. Oncotarget. 7:31413–31428. 2016. View Article : Google Scholar : PubMed/NCBI
32	Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM, Hammond EM, et al: The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature Commun. 7:123082016. View Article : Google Scholar
33	Castedo M, Perfettini JL, Roumier T and Kroemer G: Cyclin-dependent kinase-1: Linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ. 9:1287–1293. 2002. View Article : Google Scholar : PubMed/NCBI
34	Shi YX, Zhu T, Zou T, Zhuo W, Chen YX, Huang MS, Zheng W, Wang CJ, Li X, Mao XY, et al: Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma. Oncotarget. 7:85235–85243. 2016. View Article : Google Scholar : PubMed/NCBI
35	Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA, et al: Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2. Mol Cancer Ther. 15:2758–2766. 2016. View Article : Google Scholar : PubMed/NCBI
36	Lane HA and Nigg EA: Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol. 135:1701–1713. 1996. View Article : Google Scholar : PubMed/NCBI
37	Xiao D, Yue M, Su H, Ren P, Jiang J, Li F, Hu Y, Du H, Liu H and Qing G: Polo-like kinase-1 regulates Myc stabilization and activates a feedforward circuit promoting tumor cell survival. Mol Cell. 64:493–506. 2016. View Article : Google Scholar : PubMed/NCBI
38	Goldenson B and Crispino JD: The aurora kinases in cell cycle and leukemia. Oncogene. 34:537–545. 2015. View Article : Google Scholar : PubMed/NCBI
39	Woo JK, Kang JH, Shin D, Park SH, Kang K, Nho CW, Seong JK, Lee SJ and Oh SH: Daurinol enhances the efficacy of radiotherapy in lung cancer via suppression of aurora kinase a/b expression. Mol Cancer Ther. 14:1693–1704. 2015. View Article : Google Scholar : PubMed/NCBI
40	Weinstein J, Jacobsen FW, Hsu-Chen J, Wu T and Baum LG: A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4. Mol Cell Biol. 14:3350–3363. 1994. View Article : Google Scholar : PubMed/NCBI
41	Xie Q, Wu Q, Mack SC, Yang K, Kim L, Hubert CG, Flavahan WA, Chu C, Bao S and Rich JN: CDC20 maintains tumor initiating cells. Oncotarget. 6:13241–13254. 2015. View Article : Google Scholar : PubMed/NCBI
42	Choi JW, Kim Y, Lee JH and Kim YS: High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch. 463:681–687. 2013. View Article : Google Scholar : PubMed/NCBI
43	Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C and Wang H: Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol. 5:152012. View Article : Google Scholar : PubMed/NCBI
44	Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M and Kaji M: Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol. 106:423–430. 2012. View Article : Google Scholar : PubMed/NCBI
45	Han X, Liu M, Wang S, Lv G, Ma L, Zeng C and Shi Y: An integrative analysis of the putative gefitinib-resistance related genes in a lung cancer cell line model system. Curr Cancer Drug Targets. 15:423–434. 2015. View Article : Google Scholar : PubMed/NCBI
46	Davenport JW, Fernandes ER, Harris LD, Neale GA and Goorha R: The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is expressed in a cell cycle-dependent manner. Genomics. 55:113–117. 1999. View Article : Google Scholar : PubMed/NCBI
47	Chen H, Lee J, Kljavin NM, Haley B, Daemen A, Johnson L and Liang Y: Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinoma. Genes Cancer. 6:106–118. 2015.PubMed/NCBI
48	Moldovan GL, Pfander B and Jentsch S: PCNA, the maestro of the replication fork. Cell. 129:665–679. 2007. View Article : Google Scholar : PubMed/NCBI
49	Bodduluru LN, Kasala ER, Madhana RM, Barua CC, Hussain MI, Haloi P and Borah P: Naringenin ameliorates inflammation and cell proliferation in benzo(a)pyrene induced pulmonary carcinogenesis by modulating CYP1A1, NFkappaB and PCNA expression. Int Immunopharmacol. 30:102–110. 2016. View Article : Google Scholar : PubMed/NCBI
50	Chueh AC, Wong LH, Wong N and Choo KH: Variable and hierarchical size distribution of L1-retroelement-enriched CENP-A clusters within a functional human neocentromere. Hum Mol Genet. 14:85–93. 2005. View Article : Google Scholar : PubMed/NCBI
51	Folco HD, Pidoux AL, Urano T and Allshire RC: Heterochromatin and RNAi are required to establish CENP-A chromatin at centromeres. Science. 319:94–97. 2008. View Article : Google Scholar : PubMed/NCBI
52	Toh SH, Prathipati P, Motakis E, Kwoh CK, Yenamandra SP and Kuznetsov VA: A robust tool for discriminative analysis and feature selection in paired samples impacts the identification of the genes essential for reprogramming lung tissue to adenocarcinoma. BMC Genomics. 12(Suppl 3): S242011. View Article : Google Scholar : PubMed/NCBI
53	Xu L, Deng HX, Yang Y, Xia JH, Hung WY and Siddque T: Assignment of mitotic arrest deficient protein 2 (MAD2L1) to human chromosome band 5q23.3 by in situ hybridization. Cytogenet Cell Genet. 78:63–64. 1997. View Article : Google Scholar : PubMed/NCBI
54	Guo Y, Zhang X, Yang M, Miao X, Shi Y, Yao J, Tan W, Sun T, Zhao D, Yu D, et al: Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer. J Med Genet. 47:616–622. 2010. View Article : Google Scholar : PubMed/NCBI
55	Zlotnik A, Burkhardt AM and Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11:597–606. 2011. View Article : Google Scholar : PubMed/NCBI
56	Zlotnik A and Yoshie O: The chemokine superfamily revisited. Immunity. 36:705–716. 2012. View Article : Google Scholar : PubMed/NCBI
57	Wald O, Shapira OM and Izhar U: CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics. 3:26–33. 2013. View Article : Google Scholar : PubMed/NCBI
58	Suzuki M, Mohamed S, Nakajima T, Kubo R, Tian L, Fujiwara T, Suzuki H, Nagato K, Chiyo M, Motohashi S, et al: Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol. 33:113–119. 2008.PubMed/NCBI
59	Hartmann TN, Burger JA, Glodek A, Fujii N and Burger M: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
60	Ebina M, Steinberg SM, Mulshine JL and Linnoila RI: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 54:2496–2503. 1994.PubMed/NCBI
61	Matturri L, Lavezzi AM, Grignani F, Salomoni G and Roviaro GC: The prognostic value of cell proliferation in non-small cell lung cancer assessed with tritiated thymidine and anti-PCNA antibodies. Eur J Cancer. 30A:1397–1398. 1994. View Article : Google Scholar : PubMed/NCBI
62	Alemany Monraval P, Martorell Cebollada M, Salvador Villalba I and Martínez Leandro E: Study of the expression of proliferating cell nuclear antigen and p185 in non-small cell lung carcinoma. Arch Bronconeumol. 32:(In Spanish):. 165–169. 1996. View Article : Google Scholar : PubMed/NCBI
63	Castellano VM, Sotelo T, Ballestin C, Lopez-Encuentra A and Varela G: Analysis of proliferating cell nuclear antigen (PCNA) expression in 24 cases of primary non-small cell pulmonary carcinomas and correlation with survival. Arch Bronconeumol. 32:(In Spanish):. 127–131. 1996. View Article : Google Scholar : PubMed/NCBI
64	Guo X, Li D, Wu Y, Chen Y, Zhou X, Wang X, Huang X, Li X, Yang H and Xing J: Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer. Lung Cancer. 87:162–168. 2015. View Article : Google Scholar : PubMed/NCBI
65	Di JZ, Peng JY and Wang ZG: Prevalence, clinicopathological characteristics, treatment, and prognosis of intestinal metastasis of primary lung cancer: A comprehensive review. Surg Oncol. 23:72–80. 2014. View Article : Google Scholar : PubMed/NCBI
66	North CM and Christiani DC: Women and lung cancer: What is new? Semin Thorac Cardiovasc Surg. 25:87–94. 2013. View Article : Google Scholar : PubMed/NCBI
67	Lin J and Beer DG: Molecular predictors of prognosis in lung cancer. Ann Surg Oncol. 19:669–676. 2012. View Article : Google Scholar : PubMed/NCBI